I-Kazia Therapeutics Limited ibhengeze idatha entsha yangaphambi kweklinikhi ebonisa umsebenzi we-paxalisib kwiindidi ezimbini zomhlaza wobuchopho kumntwana onemfuno ephezulu kakhulu yonyango engekafikelelwa.
Le datha ingumxholo wezinto ezintathu ezifihliweyo kwiNtlanganiso yoNyaka yoMbutho waseMelika woPhando loMhlaza (AACR), eyayibanjelwe eNew Orleans, LA, ukusuka nge-8 ukuya kwi-13 ka-Epreli ngo-2022.
Izicatshulwa ezibini zezazinzulu ezisebenza kwibhubhoratri kaNjingalwazi oNcedisayo uJeffrey Rubens kwiYunivesithi yaseJohns Hopkins eBaltimore, MD, ichaza ukusetyenziswa kwe-paxalisib njengonyango lomqolo kumhlaza wengqondo ebuntwaneni owaziwa ngokuba yi-atypical teratoid / rhabdoid tumors (AT / RT). Esi sisihlandlo sokuqala ukuba idatha yokuphonononga i-paxalisib ngolu hlobo lomhlaza wobuchopho ibonakaliswe, kwaye ivula into ebalulekileyo ebonisa ukuba kukho ichiza.
I-abstract yesithathu, evela kwiqela elahlukileyo lezazinzulu kwiYunivesithi yaseJohns Hopkins, ekhokelwa nguNjingalwazi u-Eric Raabe kunye noGqr Katherine Barnett, babonise ubungqina bentsebenziswano enamandla phakathi kwe-paxalisib kunye nolunye udidi lonyango lomhlaza kumzekelo we-diffuse intrinsic pontine glioma (DIPG) . I-Paxalisib ngaphambili ibonise ubungqina bomsebenzi kwesi sifo, zombini njenge-monotherapy kwaye idibene neentlobo ezininzi zonyango lomhlaza, kwaye idatha entsha iqinisekisa ngakumbi amandla ayo kwesi sifo esinzima kakhulu.
Amaphuzu aphambili
• I-AT/RT ngumhlaza wobuchopho onqabileyo ochaphazela kakhulu iintsana kunye nabantwana abancinci. Akukho mayeza avunyiweyo e-FDA kwi-AT/RT kwaye iinketho zonyango ezikhoyo zilinganiselwe kakhulu. Bangaphantsi kwesigulana esinye kwabahlanu esiphila ngaphezu kweminyaka emibini ukusuka ekuxilongweni.
• Idatha evela kwilabhoratri kaNjingalwazi Rubens ibonisa ukuba indlela ye-PI3K idla ngokusebenza kwi-AT/RT, kwaye unyango nge-paxalisib yodwa lusebenza kwiimodeli zangaphambili zesi sifo. Ngaphezu koko, ukudibanisa nokuba yi-RG2822, i-HDAC inhibitor, okanye i-TAK580, i-MAPK inhibitor, ibonakala ngathi yandisa kakhulu ukusinda xa kuthelekiswa nonyango lwe-monotherapy.
• I-DIPG ngumhlaza wobuchopho onqabileyo odla ngokubonwa kubantwana abancinci nabafikisayo. Awekho amachiza avunyiweyo e-FDA, kwaye umndilili wobomi obuphilwayo ukusuka kuxilongo ngokuqhelekileyo uphakathi kweenyanga ezilishumi.
• Idatha yangaphambili esuka kumaqela amaninzi abaphandi, ngakumbi kwiqela likaNjingalwazi Matt Dun kwi-Hunter Medical Research Institute, ibonise ukuba i-paxalisib isebenza kakhulu kwi-DIPG kwaye idibanisa ngokubambisana kunye namachiza amaninzi omhlaza.
• Idatha esuka kuGqr Raabe no-Barnett kunye noogxa bachonga indibaniselwano yenoveli eyongezelelweyo yonyango, kunye ne-HDAC inhibitor RG2833, ebonisa ubungqina be-synergy eyomeleleyo kwimodeli yangaphambili ye-DIPG.
I-CEO ye-Kazia, uGqr James Garner, wongezelela, "Le yidatha ethembisayo kakhulu, kwaye siyabulela kwiqela lase-Johns Hopkins ngolu phando lubalulekileyo nolukhuthazayo. I-Paxalisib sele ingumxholo wesigaba se-II solingo lwezonyango oluqhubekayo kwi-DIPG kwaye isasaze i-gliomas ye-midline (NCT05009992) kwaye le datha entsha iphakamisa usetyenziso olunokwenzeka olubanzi lwechiza kumhlaza wobuchopho ebuntwaneni. Sijonge phambili ekusebenzeni neqela likaJohns Hopkins, kunye namanye amaqabane kunye nabacebisi, siwaphonononge la mathuba ngakumbi. "
INTO ONOKUYITHATHA KWELI NQAKU:
- Two abstracts by scientists working in the laboratory of Assistant Professor Jeffrey Rubens at Johns Hopkins University in Baltimore, MD, describe the use of paxalisib as a backbone therapy in a childhood brain cancer known as atypical teratoid / rhabdoid tumours (AT/RT).
- The third abstract, from a different team of scientists at Johns Hopkins University, led by Associate Professor Eric Raabe and Dr Katherine Barnett, showed evidence of strong synergy between paxalisib and another class of cancer therapies in a model of diffuse intrinsic pontine glioma (DIPG).
- Paxalisib is already the subject of an ongoing phase II clinical trial in DIPG and diffuse midline gliomas (NCT05009992) and this new data suggests potential wider applications for the drug in childhood brain cancers.
